Soligenix has regained the North American and European commercial rights to orBec (oral beclomethasone 17.21-dipropionate) from Sigma-Tau Pharmaceuticals. Soligenix is now free to commercialize or enter into commercialization agreements for its oral BDP suite of products with other parties without limitation.
According to Soligenix, orBec is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. Oral BDP has been marketed in the U.S. and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma.
In July 2011, Sigma-Tau inked a commercialization deal for orBec that included a $5 million upfront payment to Soligenix. The company also agreed to pay $11 million in potential milestones to Soligenix.
Following the Sigma-Tau deal, Soligenix reported a series of disappointing clinical trial results for orBec.
In October of this year, Sigma-Tau Pharmaceuticals appointed Jeff Hackman as its new vice president of commercial operations.